Mivacurium chloride

As a short-acting non-depolarizing benzylisoquinoline muscle relaxant, mivacurium chloride exerts a rapid and reversible muscle relaxant effect by competitively binding to N2 cholinergic receptors on the postsynaptic membrane of motor nerve endings and blocking the depolarization effect of acetylcholine. Its duration of action is only 1/3 that of atracurium, and no antagonist is required for muscle strength recovery after drug withdrawal. It is especially suitable for short-duration surgeries, tracheal intubation, and anesthesia induction for short outpatient surgeries, can effectively reduce the risk of postoperative residual neuromuscular blockade, and has high medication safety for patients with hepatic and renal insufficiency.

At present, the global market size of mivacurium chloride is approximately USD 210 million, with a compound annual growth rate maintained at around 4.2%. The core driving force for growth comes from the continuous increase in the proportion of ambulatory surgery and the standardized popularization of anesthetic muscle relaxants. In terms of the domestic market, the annual average growth rate of mivacurium chloride preparation sales in the past three years has reached 11.7%, and the terminal sales in public medical institutions exceeded RMB 320 million in 2023. The current competitive landscape is dominated by generic drugs, with only 3 domestic enterprises holding preparation approval documents, there is still a certain gap in the supply of active pharmaceutical ingredients (APIs), and it has not yet been included in the national centralized drug procurement scope.

The original research enterprise of mivacurium chloride is GlaxoSmithKline (UK), with the original brand name Mivacron, and its core compound patent expired globally in 2007. The main dosage form approved for the original product is injection, with two specifications: 5ml:10mg and 10ml:20mg, which have been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs (Third Batch)*. According to the domestic API registration platform, currently mivacurium chloride APIs from 2 enterprises have passed the approval of the Center for Drug Evaluation (CDE) and obtained A-status registration numbers, and preparation products from another 6 enterprises have been approved for marketing in China. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for mivacurium chloride API, covering the full chain of reference materials including synthetic starting materials, intermediates and degradation products. Most products are available from stock, and in-stock orders placed before 16:00 can be shipped on the same day. All products comply with the requirements of drug regulatory regulations of multiple countries such as the Chinese Pharmacopoeia and FDA, and can fully support the needs of API R&D, quality research and compliance declaration.